Literature DB >> 17643762

Risk factors for rate of decline in forced expiratory volume in one second in children and adolescents with cystic fibrosis.

Michael W Konstan1, Wayne J Morgan, Steven M Butler, David J Pasta, Marcia L Craib, Stefanie J Silva, Dennis C Stokes, Mary Ellen B Wohl, Jeffrey S Wagener, Warren E Regelmann, Charles A Johnson.   

Abstract

OBJECTIVES: To characterize the rate of decline of forced expiratory volume in 1 second (FEV(1)) in children and adolescents with cystic fibrosis and to identify and compare risk factors associated with FEV(1) decline. STUDY
DESIGN: The rate of decline in FEV(1)% predicted over 3 to 6 years in 3 different age groups was determined. Risk factors for decline were identified and compared among and within age groups as a function of disease severity with repeated-measures, mixed-model regression.
RESULTS: Mean (+/-SD) baseline FEV(1)% predicted was 88.4% +/- 20.5% for 6- to 8-year-olds (n = 1811), 85.3% +/- 20.8% for 9- to 12-year-olds (n = 1696), and 78.4% +/- 22.0% for 13- to 17-year-olds (n = 1359). Decline in FEV(1)% predicted/year was -1.12, -2.39, and -2.34, respectively. High baseline FEV(1) and persistent crackles were significant independent risk factors for decline across all age groups. Female sex, Pseudomonas aeruginosa infection, low weight-for-age, sputum, wheezing, sinusitis, pulmonary exacerbations treated with intravenous antibiotics, elevated liver test results, and pancreatic insufficiency were also identified as independent risk factors in some age groups.
CONCLUSIONS: This study identifies risk factors for FEV(1) decline in children and adolescents with cystic fibrosis. Clinicians should not be reassured by high lung function, particularly in young children, because this factor, among others, is independently associated with steeper decline in FEV(1).

Entities:  

Mesh:

Year:  2007        PMID: 17643762     DOI: 10.1016/j.jpeds.2007.03.006

Source DB:  PubMed          Journal:  J Pediatr        ISSN: 0022-3476            Impact factor:   4.406


  140 in total

1.  Initial Pseudomonas aeruginosa treatment failure is associated with exacerbations in cystic fibrosis.

Authors:  Nicole Mayer-Hamblett; Richard A Kronmal; Ronald L Gibson; Margaret Rosenfeld; George Retsch-Bogart; Miriam M Treggiari; Jane L Burns; Umer Khan; Bonnie W Ramsey
Journal:  Pediatr Pulmonol       Date:  2011-08-09

2.  Pulmonary exacerbations in cystic fibrosis with negative bacterial cultures.

Authors:  Edith T Zemanick; Brandie D Wagner; J Kirk Harris; Jeffery S Wagener; Frank J Accurso; Scott D Sagel
Journal:  Pediatr Pulmonol       Date:  2010-06

3.  Design and powering of cystic fibrosis clinical trials using rate of FEV(1) decline as an efficacy endpoint.

Authors:  M W Konstan; J S Wagener; A Yegin; S J Millar; D J Pasta; D R VanDevanter
Journal:  J Cyst Fibros       Date:  2010-06-19       Impact factor: 5.482

4.  Year-to-year changes in lung function in individuals with cystic fibrosis.

Authors:  Theodore G Liou; Eric P Elkin; David J Pasta; Joan R Jacobs; Michael W Konstan; Wayne J Morgan; Jeffrey S Wagener
Journal:  J Cyst Fibros       Date:  2010-05-14       Impact factor: 5.482

5.  Invasive Pulmonary Fungal Infections in Cystic Fibrosis.

Authors:  Carsten Schwarz; Claudia Brandt; Paul Whitaker; Sivagurunathan Sutharsan; Heino Skopnik; Silvia Gartner; Christina Smazny; Jobst F Röhmel
Journal:  Mycopathologia       Date:  2017-09-01       Impact factor: 2.574

6.  Early life growth patterns persist for 12 years and impact pulmonary outcomes in cystic fibrosis.

Authors:  Don B Sanders; Zhumin Zhang; Philip M Farrell; HuiChuan J Lai
Journal:  J Cyst Fibros       Date:  2018-02-01       Impact factor: 5.482

7.  Pseudomonas aeruginosa in vitro phenotypes distinguish cystic fibrosis infection stages and outcomes.

Authors:  Nicole Mayer-Hamblett; Margaret Rosenfeld; Ronald L Gibson; Bonnie W Ramsey; Hemantha D Kulasekara; George Z Retsch-Bogart; Wayne Morgan; Daniel J Wolter; Christopher E Pope; Laura S Houston; Bridget R Kulasekara; Umer Khan; Jane L Burns; Samuel I Miller; Lucas R Hoffman
Journal:  Am J Respir Crit Care Med       Date:  2014-08-01       Impact factor: 21.405

8.  Lumacaftor/Ivacaftor reduces pulmonary exacerbations in patients irrespective of initial changes in FEV1.

Authors:  Susanna A McColley; Michael W Konstan; Bonnie W Ramsey; J Stuart Elborn; Michael P Boyle; Claire E Wainwright; David Waltz; Montserrat Vera-Llonch; Gautham Marigowda; John G Jiang; Jaime L Rubin
Journal:  J Cyst Fibros       Date:  2018-08-23       Impact factor: 5.482

9.  Sputum biomarkers of inflammation and lung function decline in children with cystic fibrosis.

Authors:  Scott D Sagel; Brandie D Wagner; Margaret M Anthony; Peggy Emmett; Edith T Zemanick
Journal:  Am J Respir Crit Care Med       Date:  2012-08-16       Impact factor: 21.405

10.  Early Childhood Risk Factors for Decreased FEV1 at Age Six to Seven Years in Young Children with Cystic Fibrosis.

Authors:  Don B Sanders; Julia Emerson; Clement L Ren; Michael S Schechter; Ronald L Gibson; Wayne Morgan; Margaret Rosenfeld
Journal:  Ann Am Thorac Soc       Date:  2015-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.